Scolaris Content Display Scolaris Content Display

Pilates for low‐back pain

This is not the most recent version

Appendices

Appendix 1. MEDLINE search strategy

1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab,ti.
5. drug therapy.fs.
6. randomly.ab,ti.
7. trial.ab,ti.
8. groups.ab,ti.
9. or/1‐8
10. (animals not (humans and animals)).sh.
11. 9 not 10

12. dorsalgia.ti,ab.
13. exp Back Pain/
14. backache.ti,ab.
15. exp Low Back Pain/
16. (lumbar adj pain).ti,ab.
17. coccyx.ti,ab.
18. coccydynia.ti,ab.
19. sciatica.ti,ab.
20. sciatic neuropathy/
21. spondylosis.ti,ab.
22. lumbago.ti,ab.
23. back disorder$.ti,ab.
24. or/12‐23

25. exp Pilates/

26. pilates.ti,ab

27. 25 or 26

28. 11 and 24 and 27

Appendix 2. EMBASE search strategy

1 Clinical Article/
2 exp Clinical Study/
3 Clinical Trial/
4 Controlled Study/
5 Randomized Controlled Trial/
6 Major Clinical Study/
7 Double Blind Procedure/
8 Multicenter Study/
9 Single Blind Procedure/
10 Phase 3 Clinical Trial/
11 Phase 4 Clinical Trial/
12 crossover procedure/
13 placebo/
14 or/1‐13
15 allocat$.mp.
16 assign$.mp.
17 blind$.mp.
18 (clinic$ adj25 (study or trial)).mp.
19 compar$.mp.
20 control$.mp.
21 cross?over.mp.
22 factorial$.mp.
23 follow?up.mp.
24 placebo$.mp.
25 prospectiv$.mp.
26 random$.mp.
27 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).mp.
28 trial.mp.
29 (versus or vs).mp.
30 or/15‐29
31 14 and 30

32 human/
33 Nonhuman/
34 exp ANIMAL/
35 Animal Experiment/
36 33 or 34 or 35
37 32 not 36
38 31 not 36
39 37 and 38
40 38 or 39

41 dorsalgia.mp.
42 back pain.mp.
43 exp LOW BACK PAIN/
44 exp BACKACHE/
45 (lumbar adj pain).mp.
46 coccyx.mp.
47 coccydynia.mp.
48 sciatica.mp.
49 exp ISCHIALGIA/
50 spondylosis.mp.
51 lumbago.mp.
52. back disorder$.ti,ab.
53. or/41‐52

54. exp pilates

55. pilates.mp

56. 54 or 55

55. 40 and 53 and 56

Appendix 3. CINAHL search strategy

S28 S26 NOT S27
S27 (MH "Animals")
S26 S7 or S12 or S19 or S25
S25 S20 or S21 or S22 or S23 or S24
S24 volunteer*
S23 prospectiv*
S22 control*
S21 followup stud*
S20 follow‐up stud*
S19 S13 or S14 or S15 or S16 or S17 or S18
S18 (MH "Prospective Studies+")
S17 (MH "Evaluation Research+")
S16 (MH "Comparative Studies")
S15 latin square
S14 (MH "Study Design+")
S13 (MH "Random Sample")
S12 S8 or S9 or S10 or S11
S11 random*
S10 placebo*
S9 (MH "Placebos")
S8 (MH "Placebo Effect")
S7 S1 or S2 or S3 or S4 or S5 or S6
S6 triple‐blind
S5 single‐blind
S4 double‐blind
S3 clinical W3 trial
S2 "randomi?ed controlled trial*"
S1 (MH "Clinical Trials+")

S48 S35 or S43 or S47
S47 S44 or S45 or S46
S46 "lumbago"
S45 (MH "Spondylolisthesis") OR (MH "Spondylolysis")
S44 (MH "Thoracic Vertebrae")
S43 S36 or S37 or S38 or S39 or S40 or S41 or S42

S42 lumbar N2 vertebra
S41 (MH "Lumbar Vertebrae")
S40 "coccydynia" OR "back disorder*"
S39 "coccyx"
S38 "sciatica"
S37 (MH "Sciatica")
S36 (MH "Coccyx")
S35 S29 or S30 or S31 or S32 or S33 or S34
S34 lumbar N5 pain
S33 lumbar W1 pain
S32 "backache"
S31 (MH "Low Back Pain")
S30 (MH "Back Pain+")
S29 "dorsalgia"

S49 Pilates

S50 S49 and S48 and S28

Appendix 4. CENTRAL search strategy

#1 MeSH descriptor Back Pain explode all trees
#2 dorsalgia
#3 backache
#4 MeSH descriptor Low Back Pain explode all trees
#5 (lumbar next pain) or (coccyx) or (coccydynia) or (sciatica) or (spondylosis)
#6 MeSH descriptor Spine explode all trees
#7 MeSH descriptor Spinal Diseases explode all trees
#8 (lumbago) or (discitis) or (disc near degeneration) or (disc near prolapse) or (disc near herniation)
#9 spinal fusion
#10 spinal neoplasms
#11 facet near joints
#12 MeSH descriptor Intervertebral Disk explode all trees
#13 postlaminectomy
#14 arachnoiditis
#15 failed near back
#16 MeSH descriptor Cauda Equina explode all trees
#17 lumbar near vertebra*
#18 spinal near stenosis
#19 slipped near (disc* or disk*)
#20 degenerat* near (disc* or disk*)
#21 stenosis near (spine or root or spinal)
#22 displace* near (disc* or disk*)
#23 prolap* near (disc* or disk*)
#24 MeSH descriptor Sciatic Neuropathy explode all trees
#25 sciatic*
#26 back disorder*
#27 back near pain
#28 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27)
#29 pilates
#30 MeSH descriptor Pilates exp all trees
#31 29 or 30
#30 28 AND 31

Appendix 5. PEDro search strategy

Pilates AND clinical trial

Appendix 6. SPORTDiscus search strategy

S19 S10 AND S15 AND S18
S18 S16 or S17
S17 pilates
S16 DE "PILATES method"
S15 S14 or S13 or S12 or S11
S14 DE "LUMBAR vertebrae" or DE "LUMBOSACRAL region"
S13 DE "SCIATICA"
S12 low back pain
S11 DE "BACKACHE"
S10 S9 or S8 or S7 or S6 or S5 or S4 or S3 or S2 or S1
S9    single blind
S8    random allocation
S7    SU randomized controlled trial
S6    SU clinical trials
S5    clinical trials
S4    placebo
S3    controlled clinical trial
S2    double blind
S1    randomi?ed controlled trial

Appendix 7. Data extraction forms

Reviewer: ____________________________________________________________

  1. First author: ____________________________________________________

  2. Year: __________________________________________________________

  3. Citation (journal, volume, pages): ___________________________________

 

Eligibility: (tick the relevant box)

Criterion

Yes

No

Uncertain

RCT

 

 

 

Non‐specific low‐back pain (LBP)

 

 

 

At least one relevant outcome measure

 

 

 

Pilates intervention

 

 

 

 

Description of interventions in each group

(# of treatment session, session duration, program duration, co‐interventions)

1.      _______________________________________________________________________________

___________________________________________________________________________________

2.      _______________________________________________________________________________

___________________________________________________________________________________

3.      _______________________________________________________________________________

___________________________________________________________________________________

4.      _______________________________________________________________________________

____________________________________________________________________________________

Details of the included randomised controlled trials

Authors (year)

Patients

Interventions

Duration of Pilates intervention

Outcomes

Risk of Bias score

 

 

 

 

 

 

 

 

 

 

 

 

Continuous outcomes

Study:

 

# 1 ‐ Pilates

# 2‐

# 3‐

 

Mean

SD

N

Mean

SD

N

Mean

SD

N

Outcome #1

 

 

 

 

 

 

 

 

 

 

Baseline

 

 

 

 

 

 

 

 

 

 

Short term

(< 3/12 from randomisation)

 

 

 

 

 

 

 

 

 

Intermediate

(greater than 3/12, less than 12/12)

 

 

 

 

 

 

 

 

 

Long term

(greater than 12/12)

 

 

 

 

 

 

 

 

 

Outcome #2

 

 

 

 

 

 

 

 

 

 

Baseline

 

 

 

 

 

 

 

 

 

 

Short term

(< 3/12 from randomisation)

 

 

 

 

 

 

 

 

 

Intermediate

(greater than 3/12, less than 12/12)

 

 

 

 

 

 

 

 

 

Long term

(greater than 12/12)

 

 

 

 

 

 

 

 

 

Outcome #3

 

 

 

 

 

 

 

 

 

 

Baseline

 

 

 

 

 

 

 

 

 

 

Short term

(< 3/12 from randomisation)

 

 

 

 

 

 

 

 

 

Intermediate

(greater than 3/12, less than 12/12)

 

 

 

 

 

 

 

 

 

Long term

(greater than 12/12)

 

 

 

 

 

 

 

 

 

 

Appendix 8. Criteria for assessing risk of bias for internal validity (Higgins 2011)

Random sequence generation (selection bias)

Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence

There is a low risk of selection bias if the investigators describe a random component in the sequence generation process such as: referring to a random number table, using a computer random number generator, coin tossing, shuffling cards or envelopes, throwing dice, drawing of lots, minimisation (minimisation may be implemented without a random element, and this is considered to be equivalent to being random).

There is a high risk of selection bias if the investigators describe a non‐random component in the sequence generation process, such as: sequence generated by odd or even date of birth, date (or day) of admission, hospital or clinic record number; or allocation by judgement of the clinician, preference of the participant, results of a laboratory test or a series of tests, or availability of the intervention.

Allocation concealment (selection bias)

Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment

There is a low risk of selection bias if the participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web‐based and pharmacy‐controlled randomisation); sequentially numbered drug containers of identical appearance; or sequentially numbered, opaque, sealed envelopes.

There is a high risk of bias if participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on: using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non‐opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; or other explicitly unconcealed procedures.

Blinding of participants

Performance bias due to knowledge of the allocated interventions by participants during the study

There is a low risk of performance bias if blinding of participants was ensured and it was unlikely that the blinding could have been broken; or if there was no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding.

Blinding of personnel/care providers (performance bias)

Performance bias due to knowledge of the allocated interventions by personnel/care providers during the study

There is a low risk of performance bias if blinding of personnel was ensured and it was unlikely that the blinding could have been broken; or if there was no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding.

Blinding of outcome assessor (detection bias)

Detection bias due to knowledge of the allocated interventions by outcome assessors

There is low risk of detection bias if the blinding of the outcome assessment was ensured and it was unlikely that the blinding could have been broken; or if there was no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding, or:

  • for patient‐reported outcomes in which the patient was the outcome assessor (e.g. pain, disability): there is a low risk of bias for outcome assessors if there is a low risk of bias for participant blinding (Boutron 2005);

  • for outcome criteria that are clinical or therapeutic events that will be determined by the interaction between patients and care providers (e.g. co‐interventions, length of hospitalisation, treatment failure), in which the care provider is the outcome assessor: there is a low risk of bias for outcome assessors if there is a low risk of bias for care providers (Boutron 2005);

  • for outcome criteria that are assessed from data from medical forms: there is a low risk of bias if the treatment or adverse effects of the treatment could not be noticed in the extracted data (Boutron 2005).

Incomplete outcome data (attrition bias)

Attrition bias due to amount, nature or handling of incomplete outcome data

There is a low risk of attrition bias if there were no missing outcome data; reasons for missing outcome data were unlikely to be related to the true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data were balanced in numbers, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with the observed event risk was not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, the plausible effect size (difference in means or standardised difference in means) among missing outcomes was not enough to have a clinically relevant impact on observed effect size, or missing data were imputed using appropriate methods (if drop‐outs are very large, imputation using even "acceptable" methods may still suggest a high risk of bias) (van Tulder 2003). The percentage of withdrawals and drop‐outs should not exceed 20% for short‐term follow‐up and 30% for long‐term follow‐up and should not lead to substantial bias (these percentages are commonly used but arbitrary, not supported by literature) (van Tulder 2003).

Selective reporting (reporting bias)

Reporting bias due to selective outcome reporting

There is low risk of reporting bias if the study protocol is available and all of the study's pre‐specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre‐specified way, or if the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre‐specified (convincing text of this nature may be uncommon).

There is a high risk of reporting bias if not all of the study's pre‐specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre‐specified; one or more reported primary outcomes were not pre‐specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta‐analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Group similarity at baseline (selection bias)

Bias due to dissimilarity at baseline for the most important prognostic indicators. 

There is low risk of bias if groups are similar at baseline for demographic factors, value of main outcome measure(s), and important prognostic factors (examples in the field of back and neck pain are duration and severity of complaints, vocational status, percentage of patients with neurological symptoms) (van Tulder 2003).

Co‐interventions (performance bias)

Bias because co‐interventions were different across groups

There is low risk of bias if there were no co‐interventions or they were similar between the index and control groups (van Tulder 2003).

Compliance (performance bias)

Bias due to inappropriate compliance with interventions across groups

There is low risk of bias if compliance with the interventions was acceptable, based on the reported intensity/dosage, duration, number and frequency for both the index and control intervention(s). For single‐session interventions (e.g. surgery), this item is irrelevant (van Tulder 2003).

Intention‐to‐treat‐analysis

There is low risk of bias if all randomised patients were reported/analysed in the group to which they were allocated by randomisation.   

Timing of outcome assessments (detection bias)

Bias because important outcomes were not measured at the same time across groups

There is low risk of bias if all important outcome assessments for all intervention groups were measured at the same time (van Tulder 2003).

Other bias

Bias due to problems not covered elsewhere in the table

There is a low risk of bias if the study appears to be free of other sources of bias not addressed elsewhere (e.g. study funding).

Appendix 9. Assessing the clinical relevance

1.     Are the patients described in detail so that you can decide whether they are comparable to those that you see in your practice?

2.     Are the interventions and treatment settings described well enough so that you can provide the same for your patients?

3.     Were all clinically relevant outcomes measured and reported?

4.     Is the size of the effect clinically important?

5.     Are the likely treatment benefits worth the potential harms?